ESRP1 and neoplasm: Patients treated with tamoxifen with high ESRP1 expression had a significantly shorter overall survival (using the BreastMark microarray platform), and ESRP1 knockdown significantly inhibited tumor growth in vivo in endocrine-resistant ER-positive breast cancer [21].